Zacks Investment Research on MSN
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains?
BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Hospitals filled to capacity. Case counts climbing by the hour. Quarantine became routine. It was the beginning of the ...
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. BioNTech SE is among the best biotech ...
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...
9d
BioNTech Faces a Fork in the Road as May Brings Earnings, a Shareholder Vote, and Pipeline Progress
The drug candidate, Trastuzumab Pamirtecan, also holds both FDA Fast Track and Breakthrough Therapy designations. Phase 3 trials are underway, and a Biologics License Application is planned for 2026.
FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...
BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...
BioNTech (NASDAQ:BNTX) has agreed to acquire its German rival CureVac (NASDAQ:CVAC) in an all-stock transaction worth nearly $1.25B, the companies announced Thursday. Shares of CureVac (NASDAQ:CVAC) ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...
By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to start again with a new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results